These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23584348)

  • 21. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
    Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
    Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
    Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
    Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis.
    Corsi NJ; Messing EM; Sood A; Keeley J; Bronkema C; Rakic N; Jamil M; Dalela D; Arora S; Piontkowski AJ; Majdalany SE; Butaney M; Rakic I; Li P; Menon M; Rogers CG; Abdollah F
    Clin Genitourin Cancer; 2022 Dec; 20(6):e498-e505. PubMed ID: 35871040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
    Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
    Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies.
    Den Otter W; Van Moorselaar RJ; Jacobs JJ; Haar RT; Koten JW; Dobrowolski Z; Lipczynski W; Pašukonienė V; Characiejus D; Jankevičius F; Eidukevičius R; De Reijke TM
    Anticancer Res; 2013 May; 33(5):2099-105. PubMed ID: 23645761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis.
    Kang W; Cui Z; Chen Q; Zhang D; Zhang H; Jin X
    Oncotarget; 2017 Apr; 8(14):23880-23890. PubMed ID: 27823975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer.
    Barocas DA; Liu A; Burks FN; Suh RS; Schuster TG; Bradford T; Moylan DA; Knapp PM; Murtagh DS; Morris D; Dunn RL; Montie JE; Miller DC
    J Urol; 2013 Dec; 190(6):2011-6. PubMed ID: 23792129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective dose and adverse effects of maintenance Bacillus Calmette-Gue'Rin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial.
    Astram A; Khadijah A; Yuri P; Zulfan A; Mochtar CA; Danarto R; Umbas R; Hamid AR
    Acta Med Indones; 2014 Oct; 46(4):298-307. PubMed ID: 25633546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
    Hirao Y; Okajima E; Ozono S; Samma S; Sasaki K; Hiramatsu T; Babaya K; Watanabe S; Maruyama Y
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S26-30. PubMed ID: 1394812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIP.
    Kowalik C; Gee JR; Sorcini A; Moinzadeh A; Canes D
    Can J Urol; 2014 Jun; 21(3):7266-70. PubMed ID: 24978355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.
    Sylvester RJ; Oosterlinck W; Witjes JA
    Eur Urol; 2008 Apr; 53(4):709-19. PubMed ID: 18207317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.